NCT07169643招募中3 期
Darbepoetin in Patients Candidates for Liver Transplant: Randomized Clinical Trial Protocol. (EPO-LT Trial)
Fundacion Clinic per a la Recerca Biomédica1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2025年11月25日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 140
- 试验地点
- 1
- 主要终点
- to investigate the efficacy and safety of darbepoetin (DP) administration in patients on the liver transplant (LT) waiting list to reduce intraoperative red blood cell concentrate transfusion.
研究概览
简要总结
This is a national multicenter, randomized clinical trial to evaluate the the efficacy and safety of DP administration in patients on the liver transplant waiting list to reduce intraoperative red blood cell concentrate transfusion.
详细描述
Patients will be randomized to receive (1:1):
- Intervention group: Darbepoetin (DP) 1.5 mcg/kg subcutaneously, monthly (The patients will receive medication monthly until the liver transplant is performed or if it has not yet been transplanted, a maximum of 3 doses)
- Control group: Do not Darbepoetin All patients will be evaluated to rule out vitamin B12 and folic acid deficiencies, and supplementation with 1000 mcg/day and 10 mg/day, respectively, will be provided if necessary. All patients, on the liver transplant list, will receive ferric carboxymaltose 1000 mg IV (every month) according to standard clinical practice Patients will be followed for 3 months after LT
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years old
- •Patients on the official liver transplant waiting list
- •Hemoglobin (Hb) level ≤ 11.5 g/dL
- •Women of child-bearing potential* must have a negative pregnancy test in serum before the inclusion in the study and agree to use highly effective contraceptive methods during the study. Highly effective contraceptive methods will include: intrauterine device, bilateral tubal occlusion, vasectomized partner and sexual abstinence** (only if refraining from heterosexual intercourse during the period of twelve months). Hormonal contraceptive methods will be avoided due to the risk of adverse events and impairment of liver function.
- •A woman will be considered of childbearing potential, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as 0 menses for 12 months without an alternative medical cause. A high follicle stimulating hormone level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single follicle stimulating hormone measurement is insufficient. ** Sexual abstinence should only be used as a contraceptive method if it is in line with the subjects' usual and preferred lifestyle. Periodic abstinence (calendar, symptothermal, post ovulation methods) is not an acceptable method of contraception.
排除标准
- •1. Acute/subacute liver failure (see appendix 7)
- •Patients with acute-on-chronic liver failure grade III and/or MELD > 35
- •History of thrombosis, including portal vein thrombosis
- •Significant coronary artery disease (requiring angioplasty and/or coronary stent)
- •Serum ferritin > 800 ng/mL and SAT > 50%
- •Anticoagulant/antiplatelet therapy
- •History of seizures
- •Uncontrolled hypertension (requiring ≥2 antihypertensive drugs)
- •Active infection/sepsis (see appendix 8)
- •Lack of patient consent.
- •Pregnancy or breastfeeding.
- •Patients included in other clinical trials in the month before inclusion.
- •Patients with mental incapacity, language barrier, bad social support or any other reason considered by the investigator precluding adequate understanding, cooperation or compliance in the study.
研究组 & 干预措施
Darbepoetin arm
Experimental
Darbepoetin (DP) 1.5 mcg/kgsub cutaneously, monthly (The patients will receive medication monthly until the liver transplant is performed or if it has not yet been transplanted, a maximum of 3 doses)
干预措施: Darbepoetin (DP) (Drug)
结局指标
主要结局
to investigate the efficacy and safety of darbepoetin (DP) administration in patients on the liver transplant (LT) waiting list to reduce intraoperative red blood cell concentrate transfusion.
时间窗: perioperative
Difference in the percentage of patients receiving intraoperative (LT) red blood cell transfusions between the intervention group and the control group.
次要结局
- Investigate the increase in hemoglobin levels(through study completion, an average of 1 year)
- Investigate the difference in the percentage of patients receiving intraoperative and during the first 24h after LT, red blood cell concentrate transfusion between the intervention and control groups(baseline Visit , perioperative visit, month 3 postoperative)
- Investigate the difference in the percentage of patients receiving intraoperative massive transfusion between the intervention and control groups.(perioperative visit)
- Investigate the difference in the percentage of patients who developed severe postoperative complications between the intervention and control groups.(Difference in the 3-month severe postoperative complications)
- Investigate the difference in the overall cost of the transplantation from surgery to three months post-transplant, between the intervention and control groups.(three months post-transplant)
- To evaluate the difference in postoperative graft survival , between groups(the 3 month, 6, and 12 months, postoperative graft survival after liver transplantation, between groups)
- To investigate the difference in the 3 month, 6, and 12 months, postoperative patient survival after liver transplantation, between groups(in the 3 month, 6, and 12 months, postoperative patients survival after liver transplantation)
- Impact of DP treatment on the hemostatic profile of patients with chronic liver disease, comparing the changes in the following coagulation marker beta-TG at basal and 4 weeks after administration(at basal visit and month1)
- Impact of DP treatment on the changes in the PF4 profile of patients with chronic liver disease, comparing the changes in the fPF4 coagulation marker at basal and 4 weeks after administration(at basal visit and month1)
- Impact of DP treatment on the hemostatic profile of patients with chronic liver disease, comparing the fibrinogen marker at basal and 4 weeks after administration(at basal visit and month1)
- Impact of DP treatment on the hemostatic profile of patients with chronic liver disease, comparing the changes in theTM-TGA marker at basal and 4 weeks after administration(at basal visit and month1)
- Impact of DP treatment , comparing the changes in the following coagulation CTL marker at basal and 4 weeks after administration(at basal visit and month1)
- Impact of DP treatment on the fibrinolitic profile of patients with chronic liver disease, comparing the changes iD dimer markers at basal and 4 weeks after administration(at basal visit and month1)
- Impact of DP treatment comparing the changes in the TAT marker at basal and 4 weeks after administration(at basal visit and month1)
- Impact of DP treatment comparing the changes in the heptacidin marker at basal and 4 weeks after administration(at basal visit and month1)
- Impact of DP treatment on the erythropoietin marker at basal and 4 weeks after administration(at basal visit and month1)
- To explore the impact of anemia on complications of portal hypertension(through study completion, an average of 1 year)
- To explore the impact of the anemia on the quality of life measured by the EuroQol-5D scale , in both groups.(through study completion, an average of 1 year)
- To explore the predictors of poor response to DP treatment(base line visit, month 1, month 2, month 3, month 6.)
- Proportion of patients and severity of treatment-related adverse events during the study period,(through study completion, an average of 1 year)
研究者
Anna Cruceta
Clinical Research Manager
Fundacion Clinic per a la Recerca Biomédica
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant DiseaseRefractory Metastatic Colorectal CancerNCT06607458Delcath Systems Inc.90
招募中
2 期
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant DiseaseNCT06875128Delcath Systems Inc.90
招募中
不适用
A Clinical Trial to Assess the Efficacy and Tolerance of a Berberine-based Nutraceutical Formula to Aid Blood Sugar Regulation and MetabolismMetabolism DisorderNutraceuticalNCT06700915Ultimate International, Inc.80
已完成
1 期
A Safety Study of Tucatinib in Healthy and Hepatically-Impaired SubjectsHepatic ImpairmentNCT03722823Seagen Inc.37
已完成
2 期
A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and ExerciseType 2 Diabetes MellitusNCT06411275Shenzhen HighTide Biopharmaceutical Ltd.113